Annals
Established in 1927 by the American College of Physicians
:
Advanced search
box Article
 arrow  Table of Contents                
space
 arrow  PDF of this article
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box Social Bookmarking
 Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter
What's this?
box PubMed
Articles in PubMed by Author:
 arrow  Caldwell, S. H.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

The Hepatopulmonary Syndrome Masquerading as Pulmonary Langerhans-Cell Histiocytosis

right arrow Stephen H. Caldwell, MD; Kenneth Brantley, MD; John Dent, MD; Robert C. Keeley, MD; Timothy Pruett, MD; John F. Angle, MD; Michael Gaffey, MD; Peter Waldron, MD, Hepatopulmonary Syndrome Study Group.

1 July 1994 | Volume 121 Issue 1 | Pages 34-36


Langerhans-cell histiocytosis (which can take the form of histiocytosis X, eosinophilic granuloma, Abt-Letterer-Siwe disease, and Hand-Schuller-Christian disease) may involve the bone, lung, liver, hypothalamus, and pituitary [1]. Pulmonary failure is the leading cause of death in long-term survivors [2]. Liver involvement, seen in 65% of patients with the disease, may progress to sclerosing cholangitis and cirrhosis [1, 3, 4]. Liver biopsy specimens may show cirrhosis without active histiocyte infiltration [4]. Liver transplantation in hepatobiliary Langerhans cell histiocytosis has been reported [5]. The hepatopulmonary syndrome is characterized by intrapulmonary vasodilatation and hypoxemia in patients with portal hypertension [6, 7] and has a poor prognosis [8]. Liver transplantation may reverse the condition in 3 to 12 months [9-11]. To our knowledge, the hepatopulmonary syndrome has not been reported in patients with Langerhans-cell histiocytosis.


Case Report
space
up arrowTop
dotCase Report
down arrowDiscussion
down arrowAuthor & Article Info
down arrowReferences

A 15-year-old male adolescent with cyanosis and a history of Langerhans-cell histiocytosis that was previously proved by bone biopsy was referred to our institution for variceal bleeding and ascites. He had presented at the age of 2 years with diabetes insipidus and primary hypothyroidism. At that time he was treated with vinblastine, radiation, thyroxine, and desmopressin acetate.

At the age of 10 years, he had splenectomy for pancytopenia. A liver biopsy specimen showed cirrhosis Figure 1 A. At the age of 14 years, insidious dyspnea developed, and he had variceal bleeding that required endoscopic sclerotherapy. The patient did not smoke or have a history of smoking. A transbronchial lung biopsy specimen showed mild interstitial fibrosis and a nonspecific mononuclear infiltrate with absent Birbeck granules. Over the next year, the dyspnea worsened. Therapy with thyroxine and desmopressin acetate was continued, and he began to receive portable oxygen.



View larger version (83K):
[in this window]
[in a new window]
 
Figure 1. A. Liver biopsy specimen showing heavy portal fibrosis and a regenerating nodule (original magnification, x 50). B. Chest radiograph showing a mild increase in the lower lung field markings, particularly in the right lower lung field. C. Pulmonary angiogram showing the vasculature well visualized without evidence of pulmonary hypertension. The angiogram suggests a "spongy" texture to the vasculature.

 

A physical examination showed peripheral cyanosis, clubbing, and spider angiomas. He had preserved lung excursion, absent rales, mild ascites, and an enlarged liver. Serum biochemical determinations showed a cholestatic pattern: His alkaline phosphatase level was 14 µkatal/L (normal, 0.5 to 2.0 µkatal/L), his alanine aminotransferase level was 1.78 µkatal/L (normal, 0.0 to 0.58 µkatal/L), his aspartate aminotransferase level was 1.80 µkat/L (normal, 0.0 to 0.58 µkatal/L), his {gamma}-glutamyltransferase level was 6.68 µkatal/L (normal, 0.0 to 0.5 µkatal/L), his bilirubin level was 27 µmol/L (normal, 2 to 18 µmol/L), and his hemoglobin concentration was 110 g/L. The prothrombin time, electrolyte levels and renal indices were normal. Viral hepatitis test results were negative. He had normal copper studies and iron deficiency. Antinuclear and antimitochondrial antibody tests were negative. An endoscopic retrograde cholangiogram showed intrahepatic biliary sclerosis.

A chest radiograph showed a mild interstitial pattern that was more apparent in the lower lung fields (Figure 1 B.) Examination of arterial blood gas while the patient breathed room air in the sitting position showed a pH of 7.44, a PCO2 of 33 mm Hg, and a PO2 of 55 mm Hg. The estimated shunt fraction was 9% while the patient was supine and 16% while the patient was sitting. The diffusion capacity was 15 mL/min per mm Hg (57% predicted) while the patient was supine and 10 mL/min per mm Hg (38% predicted) while the patient was sitting. The forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC ratio were normal. Total lung capacity was 6.8 L (76% predicted).

A contrast echocardiogram showed evidence of intrapulmonary vasodilatation with passage of bubbles from the right ventricle to the left atrium after four cardiac cycles. Catheterization of the right side of the heart showed no intracardiac defects and a pulmonary artery pressure of 24/3 mm Hg. A pulmonary angiogram showed no dominant arteriovenous malformations Figure 1 C, and a computed tomographic scan showed no fibrocystic changes.

Based on a diagnosis of cirrhosis and the hepatopulmonary syndrome, the patient had orthotopic liver transplantation. His surgery was uneventful. He is now being treated with cyclosporine, azathioprine, and prednisone, and he continues to receive thyroxine and desmopressin acetate. Six months after surgery, he has resumed an active lifestyle and no longer uses supplemental oxygen. Examination of arterial blood gases while the patient is sitting and breathing room air show a pH of 7.4, a PCO2 of 38 mm Hg, and a PO2 of 71 mm Hg. He has a normal FVC and FEV1 and total lung capacity. His resting oxygen saturation is 96% when he is both supine and sitting and breathing room air. Although a contrast echocardiogram showed persistent passage of bubbles (showing that intrapulmonary vasodilatation has not completely resolved), he is able to maintain saturation greater than 90% with fast walking. His diffusion capacity is now 16 mL/min per mm Hg (61% predicted) while supine and 14 mL/min per mm Hg (53% predicted) while sitting, which indicates partial recovery of pulmonary vascular tone.


Discussion
space
up arrowTop
up arrowCase Report
dotDiscussion
down arrowAuthor & Article Info
down arrowReferences

This patient had cirrhosis and severe lung dysfunction in Langerhans-cell histiocytosis, a disease commonly associated with intrinsic lung disease and pulmonary failure. In this case, the presence of portal hypertension, postural changes in lung function, normal pulmonary artery pressure, and intrapulmonary vasodilatation (which was shown by contrast echocardiography) confirmed the diagnosis of the hepatopulmonary syndrome, a condition that is potentially reversible with liver transplantation [9-11]. Our patient did have mild residual lung changes attributable to pulmonary Langerhans-cell histiocytosis. However, his evaluation and the course of his condition have shown that most of his lung dysfunction was caused by the hepatopulmonary syndrome.

Clinical lung disease is seen in 40% of patients with multisystem Langerhans-cell histiocytosis [12]. Presenting findings vary widely [1]. As in the hepatopulmonary syndrome, physical signs of lung disease may be lacking, and chest radiographs may show only bilateral reticular opacities [13]. Unlike in the hepatopulmonary syndrome, "honeycombing" caused by fibrocystic changes may be seen in the upper lung fields of long-standing cases [13]. Pulmonary function test results often show a restrictive pattern, but approximately one third of patients have normal lung volumes [14]. Early histologic findings are characterized by interstitial granulomas with Langerhans-cells. However, late findings may show only nonspecific fibrosis [15].

In one study, 36 of 63 (57%) patients with stage III Langerhans-cell histiocytosis (symptomatic multiorgan disease) had evidence of pulmonary involvement [4]. Twenty-four of these 36 patients had evidence of liver disease [4]. The prevalence of lung dysfunction among those with cirrhosis was not reported. The hepatopulmonary syndrome has an estimated prevalence of 5% of cirrhotic patients [16]. In some, the symptoms of the hepatopulmonary syndrome outweigh those of cirrhosis and dominate the clinical picture [10]. Patients characteristically have cyanosis, clubbing, and stigmata of cirrhosis. A prominent reticular pattern may be seen on chest radiographs. Other findings include normal or mildly abnormal lung mechanics, low diffusion capacity, and low pulmonary artery pressures [7]. Contrast echocardiography shows the passage of bubbles from the right circulation to the left after four to five cardiac cycles [17]. Loss of vascular tone in the lungs is evident by the postural changes seen in pulmonary testing (orthodeoxia) [6, 7].

Pulmonary failure in Langerhans-cell histiocytosis is usually attributed to advanced lung involvement. Our patient actually had the hepatopulmonary syndrome. The potential reversibility of the latter makes necessary the careful distinction between the syndrome and irreversible pulmonary Langerhans-cell histiocytosis in similar patients.

The Hepatopulmonary Syndrome Study Group includes Daniel L. Metzger, MD; William C. Stevenson, MD; Michael Ishitani, MD; Rolland C. Dickson, MD (University of Virginia Health Sciences Center, Charlottesville, Virginia); and Kevin R. Dye, MD (Community Hospital of Roanoke, Roanoke, Virginia).


Author and Article Information
space
up arrowTop
up arrowCase Report
up arrowDiscussion
dotAuthor & Article Info
down arrowReferences

From the University of Virginia Health Sciences Center, Charlottesville, Virginia, and Community Hospital of the Roanoke Valley, Roanoke, Virginia.
For members of the Hepatopulmonary Syndrome Study Group and current author addresses, see end of text.
Requests for Reprints: Stephen H. Caldwell, MD, Division of Gastroenterology, Hepatology, and Nutrition, Box 145, University of Virginia Health Sciences Center, Charlottesville, VA 22908.
Acknowledgments: The authors thank Ms. Chris Spillman for assistance in manuscript preparation and Dr. David Stone for his review of this manuscript.


References
space
up arrowTop
up arrowCase Report
up arrowDiscussion
up arrowAuthor & Article Info
dotReferences

1.  Berry DH, Becton DL. Natural history of histiocytosis-8. Hematol Oncol Clin North Am. 1987; 1:23-34.

2.  Komp DM. Long-term sequelae of histiocytosis-8. Am J Ped Hematol Oncol. 1981; 3:165-8.

3.  Greenberger JS, Crocker AC, Vawter G, Jaffe N, Cassady JR. Results of treatment of 127 patients with systemic histiocytosis (Letterer-Siwe syndrome, Schuller-Christian syndrome and multifocal eosinophilic granuloma). Medicine (Baltimore). 1981; 60:311-38.

4.  Leblanc A, Hadchouel M, Jehan P, Odievre M, Alagille D. Obstructive jaundice in children with histiocytosis X. Gastroenterology. 1981; 80:134-9.

5.  Rand EB, Whitington PF. Successful orthotopic liver transplantation in two patients with liver failure due to sclerosing cholangitis with Langerhans cell histiocytosis. J Pediatr Gastroenterol Nutr. 1992; 15:202-7.

6.  Daoud FS, Reeves JT, Schaefer JW. Failure of hypoxic pulmonary vasoconstriction in patients with liver cirrhosis. J Clin Invest. 1972; 51:1076-80.

7.  Krowka MJ, Cortese DA. Pulmonary aspects of liver disease and liver transplantation. Clin Chest Med. 1989; 10:593-616.

8.  Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somastatin analogue. Chest. 1993; 104:515-21.

9.  Eriksson LS, Soderman C, Ericzon BG, Eleborg L, Wahren J, Hedenstierna G, et al. Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology. 1990; 12:1350-7.

10.  Stoller JK, Moodie D, Schiavone WA, Vogt D, Broughan T, Winkelman E, et al. Reduction of intrapulmonary shunt and resolution of digital clubbing associated with primary biliary cirrhosis after liver transplantation. Hepatology. 1990; 11:54-8.

11.  Eriksson LS. Is intrapulmonary arteriovenous shunting and hypoxemia a contraindication for liver transplantation? Hepatology. 1991; 14:575-6.

12.  Ha SY, Helms P, Fletcher M, Broadbent V, Pritchard J. Lung involvement in Langerhans' cell histiocytosis: prevalence, clinical features, and outcome. Pediatrics. 1992; 89:466-9.

13.  Basset F, Corrin B, Spencer H, Lacronique J, Roth C, Soler P, et al. Pulmonary histiocytosis X. Am Rev Respir Dis. 1978; 118:811-20.

14.  Friedman PJ, Liebow AA, Sokoloff J. Eosinophilac granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore). 1981; 60:385-96.

15.  Marcy TW, Reynolds HY. Pulmonary histiocytosis X. Lung. 1985; 163:129-50.

16.  Krowka MJ, Cortese DA. Pulmonary aspects of chronic liver disease and liver transplantation. Mayo Clin Proc. 1985; 60:407-18.

17.  Hind CR, Wong CM. Detection of pulmonary arteriovenous fistulae in patients with cirrhosis by contrast 2D echocardiography. Gut. 1981; 22:1042-5.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Eur Respir JHome page
R. Rodriguez-Roisin, M.J. Krowka, Ph. Herve, M.B. Fallon, and on behalf of the ERS Task Force Pulmonary-Hepatic
Pulmonary-Hepatic vascular Disorders (PHD)
Eur. Respir. J., November 1, 2004; 24(5): 861 - 880.
[Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 1994 by the American College of Physicians.